Developments in the Formulation and Delivery of Spray Dried Vaccines

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2017 Sep 20

PMID 28925794

Citations 25

Authors

Gaurav Kanojia

Rimko Ten Have

Peter C Soema

Henderik Frijlink

Jean-Pierre Amorij

Gideon Kersten

Affiliations

Soon will be listed here.

Abstract

Spray drying is a promising method for the stabilization of vaccines, which are usually formulated as liquids. Usually, vaccine stability is improved by spray drying in the presence of a range of excipients. Unlike freeze drying, there is no freezing step involved, thus the damage related to this step is avoided. The edge of spray drying resides in its ability for particles to be engineered to desired requirements, which can be used in various vaccine delivery methods and routes. Although several spray dried vaccines have shown encouraging preclinical results, the number of vaccines that have been tested in clinical trials is limited, indicating a relatively new area of vaccine stabilization and delivery. This article reviews the current status of spray dried vaccine formulations and delivery methods. In particular it discusses the impact of process stresses on vaccine integrity, the application of excipients in spray drying of vaccines, process and formulation optimization strategies based on Design of Experiment approaches as well as opportunities for future application of spray dried vaccine powders for vaccine delivery.

Citing Articles

New Insights on the Burst Release Kinetics of Spray-Dried PLGA Microspheres.

Michaelides K, Al Tahan M, Zhou Y, Trindade G, Cant D, Pei Y Mol Pharm. 2024; 21(12):6245-6256.

PMID: 39454183 PMC: 11615953. DOI: 10.1021/acs.molpharmaceut.4c00686.

Spray Drying of Bacterial Membrane Vesicles for Vaccine Delivery.

Fuhrmann G, Mehanny M Methods Mol Biol. 2024; 2843:163-175.

PMID: 39141300 DOI: 10.1007/978-1-0716-4055-5_11.

Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies.

Islam N, Suwandecha T, Srichana T Daru. 2024; 32(2):761-779.

PMID: 38861247 PMC: 11555000. DOI: 10.1007/s40199-024-00520-3.

Advances in Poultry Vaccines: Leveraging Biotechnology for Improving Vaccine Development, Stability, and Delivery.

Abdelaziz K, Helmy Y, Yitbarek A, Hodgins D, Sharafeldin T, Selim M Vaccines (Basel). 2024; 12(2).

PMID: 38400118 PMC: 10893217. DOI: 10.3390/vaccines12020134.

Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.

Han S, Lee P, Choi H Pharmaceutics. 2023; 15(8).

PMID: 37631328 PMC: 10458847. DOI: 10.3390/pharmaceutics15082114.

References

Duddu S, Dal Monte P . Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res. 1997; 14(5):591-5. DOI: 10.1023/a:1012144810067. View

Maa Y, Zhao L, Payne L, Chen D . Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci. 2003; 92(2):319-32. DOI: 10.1002/jps.10294. View

Huang J, Mikszta J, Ferriter M, Jiang G, Harvey N, Dyas B . Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccin. 2007; 3(3):90-3. DOI: 10.4161/hv.3.3.4011. View

Maa Y, Shu C, Ameri M, Zuleger C, Che J, Osorio J . Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm Res. 2003; 20(7):969-77. DOI: 10.1023/a:1024493719236. View

Minne A, Louahed J, Mehauden S, Baras B, Renauld J, Vanbever R . The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology. 2007; 122(3):316-25. PMC: 2266027. DOI: 10.1111/j.1365-2567.2007.02641.x. View

Chen C, Wu R, Roth L, Guillot S, Crainic R . Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2. Arch Biochem Biophys. 1997; 342(1):108-16. DOI: 10.1006/abbi.1997.0111. View

Pastor M, Esquisabel A, Talavera A, Ano G, Fernandez S, Cedre B . An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles. Int J Pharm. 2013; 448(1):247-58. DOI: 10.1016/j.ijpharm.2013.02.057. View

Tafaghodi M, Sajadi Tabassi S, Jaafari M, Zakavi S, Momen-Nejad M . Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm. 2004; 280(1-2):125-35. DOI: 10.1016/j.ijpharm.2004.05.009. View

Schule S, Schulz-Fademrecht T, Garidel P, Bechtold-Peters K, Frieb W . Stabilization of IgG1 in spray-dried powders for inhalation. Eur J Pharm Biopharm. 2008; 69(3):793-807. DOI: 10.1016/j.ejpb.2008.02.010. View

10.

Tyne A, Chan J, Shanahan E, Atmosukarto I, Chan H, Britton W . TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine. 2013; 31(40):4322-9. DOI: 10.1016/j.vaccine.2013.07.022. View

11.

Vidgren , Kublik . Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev. 2000; 29(1-2):157-177. DOI: 10.1016/s0169-409x(97)00067-7. View

12.

Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij J . Buccal and sublingual vaccine delivery. J Control Release. 2014; 190:580-92. PMC: 7114675. DOI: 10.1016/j.jconrel.2014.05.060. View

13.

Pastor M, Esquisabel A, Marquinez I, Talavera A, Pedraz J . Cellulose acetate phthalate microparticles containing Vibrio cholerae: steps toward an oral cholera vaccine. J Drug Target. 2014; 22(6):478-87. DOI: 10.3109/1061186X.2014.888071. View

14.

Jovanovic N, Bouchard A, Hofland G, Witkamp G, Crommelin D, Jiskoot W . Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res. 2004; 21(11):1955-69. DOI: 10.1023/b:pham.0000048185.09483.e7. View

15.

Maa Y, Prestrelski S . Biopharmaceutical powders: particle formation and formulation considerations. Curr Pharm Biotechnol. 2001; 1(3):283-302. DOI: 10.2174/1389201003378898. View

16.

Kanojia G, Willems G, Frijlink H, Kersten G, Soema P, Amorij J . A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine. Int J Pharm. 2016; 511(2):1098-111. DOI: 10.1016/j.ijpharm.2016.08.022. View

17.

Maltesen M, van de Weert M . Drying methods for protein pharmaceuticals. Drug Discov Today Technol. 2014; 5(2-3):e81-8. DOI: 10.1016/j.ddtec.2008.11.001. View

18.

Jones L, Cipolla D, Liu J, Shire S, Randolph T . Investigation of protein-surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. Pharm Res. 1999; 16(6):808-12. DOI: 10.1023/a:1018809632395. View

19.

Lu D, Hickey A . Pulmonary vaccine delivery. Expert Rev Vaccines. 2007; 6(2):213-26. DOI: 10.1586/14760584.6.2.213. View

20.

Ugwoke M, Agu R, Verbeke N, Kinget R . Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005; 57(11):1640-65. DOI: 10.1016/j.addr.2005.07.009. View